7 May 2021, press release
After 3 years at the helm of the Board of Directors at LEO Pharma A/S, Olivier Bohuon has decided to step down as chairman and leave the board. Present vice-chairman Anders Ekblom will take over the position until a successor is found.
Today, Olivier Bohuon, Chairman of the Board of Directors at LEO Pharma A/S, has announced that for personal reasons, he will leave the board, effective today. The search for his successor has been initiated. Present vice-chairman Anders Ekblom will take up the position on an interim basis.
“I have enjoyed heading the Board of Directors at LEO Pharma, but have decided to step down for personal reasons. I am proud of what we have managed to achieve during my three years on the Board of Directors, and to see a strong company, that stands before a very exciting future with global launches of new innovative treatments and implementing a new ownership structure,” said Olivier Bohuon.
“We of course fully respect Olivier’s decision to leave the board, and I would like to express my sincere thanks to him for his tremendous efforts in setting the direction for the transformation of LEO Pharma and to becoming a global leader in the innovative space of medical dermatology. Olivier has been instrumental in establishing a strong global leadership team and laying out the path for an ambitious growth strategy towards 2030. We have initiated the search for the right successor to take LEO Pharma through the next phases of realizing the strategy,” said Lars Olsen, Chairman of the Board of Trustees at the LEO Foundation.
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. [In 2020, the company generated net sales of DKK 10,133 million].
For more information, please visit www.LEO-Pharma.com
About the LEO Foundation
The LEO Foundation is one of Denmark’s largest commercial foundations and an engaged owner of the pharmaceutical company LEO Pharma. The Foundation’s main objective is to ensure the company’s long-term development and success. Besides the ownership, the Foundation provides philanthropic grants with the aim to support the best international research in skin diseases and make Denmark a global beacon for skin research.
Head of Communication and Public Affairs, the LEO Foundation
Tel: +45 20 49 68 69